

Antonio Vitiello

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8437022/antonio-vitiello-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53
papers

614
citations

16
h-index

22
g-index

61
ext. papers

905
ext. citations

3.1
avg, IF

6.12
L-index

| # | Paper | IF | Citations |
|----|--|-----|-----------|
| 53 | The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?. <i>European Journal of Clinical Pharmacology</i> , 2020 , 76, 1615-1618 | 2.8 | 44 |
| 52 | Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. <i>Life Sciences</i> , 2020 , 262, 118510 | 6.8 | 32 |
| 51 | COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-4 | 2.7 | 28 |
| 50 | Therapeutic Strategies for SARS-CoV-2 acting on ACE-2. <i>European Journal of Pharmaceutical Sciences</i> , 2021 , 156, 105579 | 5.1 | 28 |
| 49 | Efficacy of synthetic glucocorticoids in COVID-19 endothelites. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021 , 394, 1003-1007 | 3.4 | 28 |
| 48 | Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study. <i>BMC Pharmacology & Toxicology</i> , 2018 , 19, 16 | 2.6 | 27 |
| 47 | Remdesivir versus ritonavir/lopinavir in COVID-19 patients. <i>Irish Journal of Medical Science</i> , 2021 , 190, 1249-1250 | 1.9 | 26 |
| 46 | Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?. <i>European Journal of Pharmacology</i> , 2020 , 883, 173373 | 5.3 | 26 |
| 45 | Colchicine and SARS-CoV-2: Management of the hyperinflammatory state. <i>Respiratory Medicine</i> , 2021 , 178, 106322 | 4.6 | 26 |
| 44 | Sacubitril, valsartan and SARS-CoV-2. <i>BMJ Evidence-Based Medicine</i> , 2020 , | 2.7 | 25 |
| 43 | Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. <i>Human Immunology</i> , 2021 , 82, 264-269 | 2.3 | 23 |
| 42 | In vitro model of stromal and epithelial immortalized endometriotic cells. <i>Journal of Cellular Biochemistry</i> , 2012 , 113, 1292-301 | 4.7 | 22 |
| 41 | Drugs acting on the renin-angiotensin system and SARS-CoV-2. <i>Drug Discovery Today</i> , 2021 , 26, 870-874 | 8.8 | 22 |
| 40 | Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?. <i>Irish Journal of Medical Science</i> , 2021 , 190, 1637-1638 | 1.9 | 21 |
| 39 | Remdesivir and COVID-19. <i>Irish Journal of Medical Science</i> , 2021 , 190, 1237-1238 | 1.9 | 19 |
| 38 | COVID-19 vaccines and decreased transmission of SARS-CoV-2. <i>Inflammopharmacology</i> , 2021 , 29, 1357-1360 | 3.6 | 16 |
| 37 | The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced. <i>Egyptian Liver Journal</i> , 2021 , 11, 11 | 1.6 | 16 |

| | | | |
|----|--|-----|----|
| 36 | Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. <i>Medical Hypotheses</i> , 2021 , 147, 110486 | 3.8 | 16 |
| 35 | COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. <i>Irish Journal of Medical Science</i> , 2021 , 1 | 1.9 | 14 |
| 34 | Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times?. <i>Indian Journal of Pharmacology</i> , 2020 , 52, 441-442 | 2.5 | 13 |
| 33 | Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia. <i>Italian Journal of Medicine</i> , 2020 , | 0.5 | 12 |
| 32 | Potential pharmacological approach in the regulation of angiotensin-II conversion enzyme and dipeptidyl-peptidase 4 in diabetic COVID-19 patients. <i>Italian Journal of Medicine</i> , 2021 , 15, | 0.5 | 12 |
| 31 | The Central Role of Clinical Nutrition in COVID-19 Patients During and After Hospitalization in Intensive Care Unit. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-5 | 2.7 | 12 |
| 30 | Scientific Hypothesis for Treatment of COVID-19 Lung Lesions by Adjusting ACE/ACE2 Imbalance. <i>Cardiovascular Toxicology</i> , 2021 , 21, 498-503 | 3.4 | 11 |
| 29 | Brief review of the mRNA vaccines COVID-19. <i>Inflammopharmacology</i> , 2021 , 29, 645-649 | 5.1 | 11 |
| 28 | Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients. <i>Wiener Klinische Wochenschrift</i> , 2021 , 133, 983-988 | 2.3 | 10 |
| 27 | Correlation between the use of statins and COVID-19: what do we know?. <i>BMJ Evidence-Based Medicine</i> , 2020 , | 2.7 | 9 |
| 26 | What will be the role of molnupiravir in the treatment of COVID-19 infection?. <i>Drugs and Therapy Perspectives</i> , 2021 , 37, 1-2 | 1.5 | 6 |
| 25 | Identification of protein-protein interactions of human HtrA1. <i>Frontiers in Bioscience - Elite</i> , 2011 , 3, 1493-1496 | 3.9 | 6 |
| 24 | Sars-Cov-2 and risk of antiviral drug resistance. <i>Irish Journal of Medical Science</i> , 2021 , 1 | 1.9 | 6 |
| 23 | The advantages of drug treatment with statins in patients with SARS-CoV-2 infection. <i>Wiener Klinische Wochenschrift</i> , 2021 , 133, 958-965 | 2.3 | 6 |
| 22 | The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021 , 394, 1589-1593 | 3.4 | 5 |
| 21 | Plausible Positive Effects of Statins in COVID-19 Patient. <i>Cardiovascular Toxicology</i> , 2021 , 21, 781-789 | 3.4 | 5 |
| 20 | Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19. <i>Lung India</i> , 2021 , 38, S129-S130 | 1.1 | 5 |
| 19 | From HTA to HTCLA: The Clinic and Logistics to Support Health Technology Assessments.. <i>Hospital Pharmacy</i> , 2022 , 57, 5-6 | 1.1 | 3 |

| | | | |
|----|--|-----|---|
| 18 | Low Molecular Weight Heparin, Anti-inflammatory/Immunoregulatory and Antiviral Effects, a Short Update. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1 | 3.9 | 3 |
| 17 | Pregnancy and COVID-19, focus on vaccine and pharmacological treatment.. <i>Journal of Reproductive Immunology</i> , 2022 , 151, 103630 | 4.2 | 3 |
| 16 | Worldwide Recommendations and Therapies for Multiple Sclerosis: Are They Safe in the COVID-19 Pandemic Period?. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-2 | 2.7 | 1 |
| 15 | A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?. <i>Immunologic Research</i> , 2021 , 1 | 4.3 | 1 |
| 14 | Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection. <i>Molecular Biology Reports</i> , 2021 , 49, 827 | 2.8 | 1 |
| 13 | Clinical Pharmacology Aspects in Patients Treated with TNF Inhibitors During SARS-Cov-2 Pandemic. <i>Advanced Pharmaceutical Bulletin</i> , 2020 , 11, 393-394 | 4.5 | 1 |
| 12 | Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021 , 1 | 3.4 | 1 |
| 11 | The impact of COVID-19 in diabetic patient. <i>Archives of Medicine and Health Sciences</i> , 2020 , 8, 167 | 0.5 | 1 |
| 10 | Antidiabetes Agents against Sars-Cov-2 Infection. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-4 | 2.7 | 1 |
| 9 | COVID-19 vaccination in pregnancy. <i>Drugs and Therapy Perspectives</i> , 2021 , 37, 1-2 | 1.5 | 1 |
| 8 | Logistics management provides greater efficiency, governance and compliance. <i>International Journal of Clinical Pharmacy</i> , 2021 , 43, 1431-1435 | 2.3 | 1 |
| 7 | Pleiotropic effects of AT-1 receptor antagonists in hypoxia induced by cardiac ischaemia.. <i>Inflammopharmacology</i> , 2022 , 1 | 5.1 | 1 |
| 6 | Could Decreased Reporting of Suspected Adverse Reactions Generate Future Safety Concerns?. <i>Hospital Pharmacy</i> , 001857872110690 | 1.1 | 0 |
| 5 | Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021 , 2, 100056 | 3 | 0 |
| 4 | The Role of Vitamin C in the Treatment of Sepsis. <i>Drugs and Therapy Perspectives</i> , 1 | 1.5 | |
| 3 | Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment. <i>Egyptian Heart Journal</i> , 2021 , 73, 103 | 1.3 | |
| 2 | COVID-19 global pandemic: vaccines and new monoclonal antibodies, aspects to be clarified. <i>Immunologic Research</i> , 2021 , 69, 115-116 | 4.3 | |
| 1 | Statins in Alzheimer's disease (AD).. <i>European Journal of Clinical Pharmacology</i> , 2022 , 1 | 2.8 | |

